Champions Oncology

Champions Oncology was founded by some of the world’s most renowned specialists in the field of cancer diagnosis, treatment, and research. The Company's team is comprised of seasoned oncology professionals passionately dedicated to working with customers to accelerate oncology drug development, improve outcomes and extend lives. Champions Oncology's core platform, the Champions TumorGraft offers an enhanced xenograft mouse avatar model for growing and testing human tumors.
Type
Public
HQ
Hackensack, US
Founded
2007
Size (employees)
60 (est)+6%
Champions Oncology was founded in 2007 and is headquartered in Hackensack, US

Key People at Champions Oncology

Joel Ackerman

Joel Ackerman

CEO
Ronnie Morris

Ronnie Morris

President
Scott Tobin

Scott Tobin

Director
Misti Ushio

Misti Ushio

Involved

Champions Oncology Office Locations

Champions Oncology has offices in Hackensack, Baltimore and London
Hackensack, US (HQ)
307 1 University Plaza Dr
London, GB
2 Royal College St
Baltimore, US
602 855 N Wolfe St

Champions Oncology Data and Metrics

Champions Oncology Financial Metrics

Champions Oncology's revenue was reported to be $11.2 m in FY, 2016 which is a 26% increase from the previous period.
USD

Revenue (FY, 2016)

11.2 m

Revenue growth (FY, 2015 - FY, 2016), %

26%

Net income (FY, 2016)

(10.4 m)

EBIT (FY, 2016)

(10.3 m)

Market capitalization (21-Jul-2017)

29 m

Cash (31-Jan-2017)

3.5 m
Champions Oncology's current market capitalization is $29 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

11.6 m8.9 m11.2 m

Revenue growth, %

(23%)26%

Sales and marketing expense

3.4 m

R&D expense

4.2 m

General and administrative expense

5.2 m

Operating expense total

17.8 m22.1 m21.5 m

EBIT

(6.3 m)(13.2 m)(10.3 m)

EBIT margin, %

(54%)(149%)(92%)

Net Income

(7.4 m)(13.1 m)(10.4 m)
USDFY, 2014FY, 2015FY, 2016

Cash

5.9 m9.4 m

Accounts Receivable

1.3 m1.1 m1.3 m

Inventories

383 k346 k443 k

Current Assets

7.6 m10.8 m4.3 m

PP&E

434 k452 k618 k

Goodwill

669 k669 k669 k

Total Assets

8.9 m12 m5.8 m

Accounts Payable

981 k1.4 m1.9 m

Current Liabilities

3.7 m3.8 m5.3 m

Total Liabilities

5.5 m

Additional Paid-in Capital

43.3 m61.2 m63.9 m

Retained Earnings

(38.9 m)(52 m)(62.5 m)

Total Equity

3.2 m8.1 m238 k

Financial Leverage

2.8 x1.5 x24.3 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

3.1 m575 k182 k6.8 m4.2 m3.3 m4.5 m4.3 m3.5 m

Accounts Receivable

925 k1.1 m1.1 m1.5 m1.9 m2.1 m1.6 m1.9 m2 m

Current Assets

4.4 m2.1 m1.5 m8.6 m6.3 m5.8 m6.4 m6.7 m6.1 m

PP&E

411 k395 k469 k445 k420 k514 k590 k561 k672 k

Goodwill

669 k669 k669 k669 k669 k669 k669 k669 k669 k

Total Assets

5.7 m3.3 m2.8 m9.8 m7.6 m7.1 m7.8 m8 m7.5 m

Accounts Payable

1.3 m1.6 m1.4 m1.4 m1.3 m1.5 m1.5 m1.2 m1.3 m

Current Liabilities

3.4 m3.9 m6.3 m3.8 m3.3 m4.6 m4.4 m4.6 m5.3 m

Additional Paid-in Capital

44.1 m44.9 m45.4 m62.1 m62.8 m63.4 m69.4 m70 m70.2 m

Retained Earnings

(42.4 m)(45.6 m)(48.4 m)(54.9 m)(57.5 m)(59.9 m)(65 m)(65.5 m)(66.9 m)

Total Equity

439 k5.9 m4.1 m2.3 m3.2 m3.2 m2 m

Financial Leverage

12.9 x1.7 x1.8 x3.2 x2.5 x2.5 x3.7 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(7.4 m)(13.1 m)(10.4 m)

Depreciation and Amortization

213 k214 k156 k

Accounts Receivable

(825 k)265 k(282 k)

Accounts Payable

(223 k)433 k482 k

Cash From Operating Activities

(3.4 m)(9.6 m)(6.5 m)

Purchases of PP&E

(234 k)(119 k)(322 k)

Cash From Investing Activities

(234 k)(114 k)(322 k)

Cash From Financing Activities

21 k13.2 m2 k
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Accounts Receivable

925 k1.1 m1.1 m1.5 m1.9 m2.1 m1.6 m1.9 m2 m

Accounts Payable

1.3 m1.6 m1.4 m1.4 m1.3 m1.5 m1.5 m1.2 m1.3 m
Y, 2017

Financial Leverage

3.7 x

Champions Oncology Market Value History

Champions Oncology Online and Social Media Presence

Champions Oncology Company Life and Culture

You may also be interested in